Novelion Therapeutics (NVLN) Given Daily Media Sentiment Rating of 0.13
News articles about Novelion Therapeutics (NASDAQ:NVLN) (TSE:QLT) have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novelion Therapeutics earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.8434794304083 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Novelion Therapeutics (NASDAQ NVLN) traded up 2.6378% during trading on Wednesday, hitting $6.9999. The stock had a trading volume of 35,603 shares. The firm’s 50-day moving average price is $7.93 and its 200-day moving average price is $9.41. The stock’s market cap is $130.53 million. Novelion Therapeutics has a 1-year low of $6.62 and a 1-year high of $13.80.
Novelion Therapeutics (NASDAQ:NVLN) (TSE:QLT) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.04). The firm had revenue of $40.90 million during the quarter, compared to analyst estimates of $36.86 million. On average, equities research analysts predict that Novelion Therapeutics will post ($1.66) earnings per share for the current fiscal year.
A number of research firms have recently weighed in on NVLN. ValuEngine cut Novelion Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday. Royal Bank Of Canada set a $9.00 price target on Novelion Therapeutics and gave the stock a “hold” rating in a report on Tuesday, August 8th. Zacks Investment Research raised Novelion Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, Bloom Burton reissued an “accumulate” rating on shares of Novelion Therapeutics in a report on Monday, June 19th.
ILLEGAL ACTIVITY NOTICE: “Novelion Therapeutics (NVLN) Given Daily Media Sentiment Rating of 0.13” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/13/novelion-therapeutics-nvln-given-daily-media-sentiment-rating-of-0-13.html.
Novelion Therapeutics Company Profile
Novelion Therapeutics Inc, formerly QLT Inc, is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development.
Receive News & Stock Ratings for Novelion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics Inc. and related stocks with our FREE daily email newsletter.